Business
New Data Insights Unveiled at ASN Kidney Week 2023 Point to the Impact of the Tablo® Hemodialysis System on Equitable Kidney Care
Studies reinforce the influence of new technology on effective, efficient kidney care SAN JOSE, Calif.--(BUSINESS WIRE)-- Outset Medical, Inc. (Nasdaq: OM)
About this update from Outset Medical, Inc.
[{"type":"text","content":"\nStudies reinforce the influence of new technology on effective, efficient kidney care\n\n\n SAN JOSE, Calif.--(BUSINESS WIRE)--\nOutset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company reducing the cost and complexity of dialysis with its Tablo® Hemodialysis System, today announced significant data findings on how the use of Tablo increases racial diversity among users, enhances patient outcomes in the Medicare fee-for-service population, and notably decreases hospital transfers in rural Alaskan communities.\n\n\nThe five abstracts will be showcased at the American Society of Nephrology’s (ASN) Kidney Week 2023 in Philadelphia, PA, which runs November 2-5. The annual event gathers more than 10,000 kidney care professionals from across the globe, offering a forum to delve into the latest advancements in nephrology and to collaborate on kidney care innovation.\n\n\n\"The research abstracts we're presenting at ASN Kidney Week are more than data points; they are a testament to Tablo's adaptability, versatility and its profound impact on equitable healthcare,” said Michael Aragon, MD, Chief Medical Officer of Outset Medical. “We're shining a spotlight on the concrete solutions that our data has revealed, solutions that transcend barriers in user diversity, Medicare adoption, rural healthcare and more.”\n\n\nNotable Abstracts & Findings:\n\n\n\nCharacteristics of the First 500 Tablo Home Hemodialysis (HHD) Users – This retrospective analysis showcases a slightly older and more racially diverse demographic, underscoring the importance of achieving equity across all demographic strata for successful home adoption in the U.S.\n\n\n\n\nCharacteristics of Tablo Home Hemodialysis Users in Medicare Fee-For-Service – This early look at Tablo HHD patients in the Medicare fee-for-service population reveals a diverse, catheter-dependent patient group, illuminating a path toward a more inclusive future for kidney care.\n\n\n\n\nPatient-Reported Outcomes (PRO) among Patients Receiving Home Hemodialysis – In this prospective study of 57 patients using Tablo for HHD, preliminary results reveal improved self-reported physical health and reduced symptoms of insomnia, underscoring the positive impact of Tablo-enabled home dialysis on patients' well-being.\n\n\n\n\nRural Alaskan Experience Insourcing Innovative Dialysis Technology –...